International
Women who have had the HPV jab are less likely to encounter high-grade vulvovaginal lesions - precancerous growths on the vulva and vagina - according to Swedish scientists. They looked at the health records of 778,943 Swedish women, around a third of whom (256,353) had been vaccinated with the quadrivalent HPV vaccine, and followed up for between 9.3 and 17 years. During that time, 98 vaccinated women developed high-grade vulvovaginal lesions, compared with 547 unvaccinated women. So, vaccinated women were around a third less likely (37%) to develop lesions than the unvaccinated. They found the HPV jab was most effective in preventing these precancerous growths when it was administered before the age of 17.
From:
Quadrivalent Human Papillomavirus Vaccine and High-Grade Vulvovaginal Lesions
About The Study: In this study, quadrivalent human papillomavirus (HPV) vaccination was associated with reduced risk of high-grade vulvovaginal lesions, suggesting that expanding vaccination, especially at younger ages, could help prevent high-grade vulvovaginal lesions.
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
